NEVIRAPINE (nevirapine) by Viatris (2) is non-nucleoside reverse transcriptase inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults, older. First approved in 2012.
Drug data last refreshed 19h ago
Non-Nucleoside Reverse Transcriptase Inhibitors
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children
Worked on NEVIRAPINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.